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Abstract
An important goal for cystic fibrosis (CF) gene therapy is to achieve long-term
functional correction. While many vector options have been evaluated, integrating
vectors have the greatest potential to maintain stable expression over time without a
requirement for repeated administration. In this chapter, we discuss the importance
of correcting the appropriate cell types, options for integrating vectors, animal models
for CF gene therapy, and clinically relevant endpoint measurements. Lentiviral
vectors are a promising option for CF gene therapy, as they integrate into the host
genome and persistently express a transgene of interest. Airway cell tropism can be
conferred by pseudotyping. Nonviral vectors such as DNA transposons can also
integrate into the genome. Recent advances in hybrid viral/transposon vector
technology improve the ability to deliver transposons to the airways in vivo. Integrat‐
ing vector technology and new animal models have allowed considerable progress
toward the goal of using gene therapy to correct life-long genetic diseases such as CF.
Keywords: lentivirus, transposons, animal models, progenitor cells, genotoxicity
1. Introduction
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene, a cAMP-regulated anion channel. While our knowledge of CFTR
function has advanced greatly since the discovery of the gene in 1989, CF remains fatal [1, 2].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
While CF is a multi-organ system disease, most people with CF die of progressive lung disease
that begins early in childhood and is characterized by chronic bacterial infection and inflam‐
mation [2]. Nearly 90% of CF patients have at least one copy of the ΔF508 mutation, but there
are >2,000 disease causing mutations that result in a range of disease severities [2]. These
mutations can be divided into six classes based on the type and consequence of the mutation
(Table 1): class I, no synthesis; class II, defective processing; class III, defective regulation; class
IV, altered conductance; class V, reduced synthesis; and class VI, accelerated turnover [3].
However, new mutations continue to be identified and one mutation may fit into more than
one category by disrupting CFTR transcription, protein trafficking, or protein regulation in
more than one way. Pharmacologic approaches aimed at activating alternative ion transport
pathways [4-7], reducing inflammation [8, 9], and inhibiting or eliminating bacterial infection
[10, 11] are active areas of therapeutic development. There is also intense interest in identifying
interventions that might restore function to the mutant protein [5, 6, 12, 13]. The promise of
restoring function to mutant protein was recently validated in a clinical trial for the CFTR
conductance mutation G551D present in 2%–3% of CF patients [6]. However, unlike small
molecule potentiators or correctors, a CFTR gene replacement approach would be efficacious
regardless of the disease causing mutation and is potentially a single dose, life-long curative
therapeutic strategy for a devastating disease.
Class ~Frequency Mutation Type Common Representative CFTR Protein Outcome
I 10% Nonsense, splice G542X No CFTR
II 70% Missense ∆F508 Defective Processing
III 2%–3% Missense G511D Defective Regulation
IV <2% Missense R117H Altered Conductance
V <1% Missense, splice 3349+10KB Reduced Synthesis
VI <1% Missense N287Y Accelerated Turnover
Table 1. Six classes of mutations in CFTR that result in CF disease [3, 14, 15].
There are a great number of vector options for CFTR gene delivery. Non-integrating viral
vectors (i.e., adenovirus or adeno-associated virus) and non-integrating nonviral vectors (i.e.,
plasmid DNA or in vitro transcribed RNA) each have important attributes and have resulted
in significant advances in the CF gene therapy field (reviewed in [16-18]). However, potential
limitations to these episomal expression systems may include gradual decreases in transgene
expression over time and limiting host immune responses following vector readministration.
These pitfalls could be avoided if a therapeutic transgene is stably integrated into the genome
of a progenitor cell population. Thus, in this chapter, we focus on the use of integrating vectors
for gene delivery, although some of the topics covered will be relevant to multiple vector
systems.
This chapter discusses the common and emerging options for integrating vectors and efforts
to deliver integrating vectors to CF animal models. Defining “curing CF with gene therapy”
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is not nearly as simple as it appears at first glance. As such, we explore a variety of relevant
outcome measures. In addition, there are challenges that need to be taken into consideration
for pre-clinical and clinical in vivo studies, such as: delivery, efficiency, persistence, the
potential for insertional mutagenesis, and cell types to transduce.
2. Correcting the appropriate cells
Because pulmonary disease is generally the most life-limiting complication of CF, gene therapy
strategies focus on lung delivery of CFTR. Regardless of the gene delivery tool, an important
consideration for CF gene therapy is the target cell. In the proximal airways, CFTR is normally
most abundant in surface epithelial cells including ciliated cells, surface columnar cells, and
submucosal gland epithelia (SMGs) [19]; in distal airways only superficial epithelia express
CFTR. With this information in mind, we face two important questions. 1) What cell types need
to be transduced to attain lasting expression? 2) What percentage of cells needs to be trans‐
duced to correct CF lung disease? A goal of gene transfer to the pulmonary epithelium with
integrating vectors is to correct the CFTR defect in a population of cells that could pass the
corrected gene to their progeny, thus eliminating the need for vector readministration. There
appear to be several epithelial cell types in the lung that provide these functions, which has
led to controversy regarding which cells to target for CF gene therapy. Arguments can be made
in support of the necessity to correct basal cells [20, 21] and non-ciliated columnar cells of the
airways [22-24], SMGs [25-27], club cells [28, 29], and alveolar type II cells [30, 31] in the distal
lung.
Compelling evidence from both in vitro and in vivo studies indicate that basal cells are
multipotent proximal airway progenitor cells that repopulate pulmonary epithelia under
normal conditions and during regeneration (reviewed in [32-34]). Cell-labeling experiments
with transgenic mice show that basal cells give rise to labeled basal, ciliated, and club cells,
thus fulfilling the definition of progenitor cells [35, 36]. Several studies suggest that basal cells
from human trachea or bronchi will repopulate denuded tracheal xenografts or differentiated
epithelial cells in vitro [37-40]. Hematopoietic stem cells are an example showing that a single
stem cell type can reconstitute a whole organ; however, there is no convincing evidence that
a multipotent airway stem cell is capable of replenishing all regions of the intrapulmonary
epithelium. The current literature supports that tracheal, bronchiolar, and alveolar epithelia
are maintained by regionally distinct progenitor cell lineages.
What percentage of cells needs to be transduced to functionally correct the CF phenotype in
vivo? This is one of the most important questions in the field of CF gene therapy, but remains
unanswered. At least five studies examined the relationship between percentage of cells
expressing CFTR and transepithelial Cl- secretion [41-45]. With relatively good agreement, they
suggest that expressing CFTR in 5%–15% of cells restores Cl- secretion to near wild-type levels.
As such, the benchmark of correcting ~10% of the cells is often cited. However, there are many
caveats to this number. Indeed one limitation is that many of these studies were performed
using in vitro models. In addition, as discussed below, other studies suggest that defective
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HCO3- transport through CFTR might be more relevant to early disease pathogenesis than
Cl- secretion [46-49]. The relationships between HCO3- secretion, airway surface liquid pH,
bacterial killing, mucociliary clearance, and mucus viscosity may be as important as Cl-
secretion as metrics for disease correction. The short answer to the question posed above is
“we do not know”; however, given current animal models and improved vector technologies,
the experiments necessary to address the question are feasible. Indeed, as we discuss below,
existing vector technologies are being optimized for lung gene transfer and novel integrating
vectors are being engineered.
3. Options for integrating gene delivery
3.1. Lentivirus
Lentiviruses comprise a genus of the virus family Retroviridae. All retroviruses are defined by
the ability to reverse transcribe their RNA genome and integrate proviral DNA into the genome
of the host cell [50]. Several features of lentiviral vectors (LVs) make them attractive vehicles
for delivering therapeutic genes, including their large coding capacity, efficient gene transfer,
persistent expression, directed tropism via pseudotyping, and lack of virus-encoded proteins
that could elicit undesirable immune responses [51-53]. Unlike gamma-retroviral vectors such
as murine Moloney leukemia virus (MMLV)-based vectors, the pre-integration complex of
lentiviruses can transverse the nuclear envelope and integrate its cargo into the genomes of
non-dividing cells [54]. The first recombinant lentiviral vectors were based on human immu‐
nodeficiency virus type-1 (HIV-1) and remain the most widely used lentiviral vector for gene
transfer applications [55]. The earliest recombinant HIV-1 viruses were created in the late 1980s
and were used to study HIV-1 biology [56].
Beginning in the 1990s and continuing to this day, there have been significant strides in
improving the safety and utility of HIV-based gene transfer vectors (reviewed in [50]). To
reduce  pathogenicity  and  render  the  vector  replication  incompetent,  most  modern  HIV
production systems are divided into four expression plasmids (Figure 1A):  1)  a plasmid
containing the transgene of interest flanked by the HIV long terminal repeats (LTRs); 2) a
packaging plasmid expressing the necessary structural and enzymatic proteins; 3) a separate
plasmid expressing HIV rev; and 4) an envelope glycoprotein expression plasmid. Multi‐
ple viral proteins, such as nef, vif, vpu, env, and vpr, have been deleted as well as much
of the U3 region of the 3’LTR. This latter deletion removes promoter and enhancer activity
from  the  LTR  and  has  been  termed  a  self-inactivating  (SIN)  modified  vector  [57].  The
woodchuck  hepatitis  virus  posttranscriptional  regulatory  element  (wPRE)  is  a  common
addition to LV vectors and functions to increase RNA stability, resulting in higher levels
of transgene expression [58, 59].
Cystic Fibrosis in the Light of New Research330
Figure 1. Schematics of integrating transgene delivery systems. A) HIV-based lentiviral vectors are produced by four
plasmid transfection. The gag/pol plasmid supplies structural and enzymatic proteins; the env plasmid supplies the
envelope glycoprotein (typically VSV-G); rev is delivered in trans via its own plasmid. The “gene of interest” (goi) is
flanked by the long terminal repeats (LTRs) and driven by a heterologous promoter. Only the genetic material flanked
by the LTRs is packaged and integrated into the host genome. B) Recombinant DNA transposons are typically deliv‐
ered as a two-part plasmid system. Transposase catalyzes the transposition of the genetic material flanked by the ap‐
propriate terminal repeats (TRs) from the plasmid and into the host genome. C) DNA transposons can also be
delivered by viral vectors to improve delivery efficiency. One viral vector carries the DNA transposon and the other
carries the transposase. The goi is flanked by the transposon TRs, which in turn are flanked by the viral vector inverted
terminal repeats (ITRs). Once inside the cell, transposition functions as described in B.
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HIV-based LV delivery of CFTR is a promising option for CF gene therapy. In proof of principle
experiments using reporter genes, HIV conferred gene transfer to both ciliated and basal cells
of the mouse, sheep, marmoset, and ferret airways [60]. Xenografts transduced with HIV
expressing CFTR achieved functional correction as assessed by the measurement of transepi‐
thelial potential difference [61]. In a CF mouse model, delivery of CFTR by HIV resulted in
sustainable transgene expression for 18 months in ciliated, non-ciliated, and basal cells [53]
and partially recovered the anion channel defect [62]. These findings support HIV as a vector
candidate for CF gene therapy. Further studies in a large animal CF model to restore anion
channel defect to rescue pH and bacterial killing are important next steps in validating this
vector for CF gene therapy.
For LVs, the native envelope glycoprotein is deleted and a heterologous envelope is supplied.
This strategy, termed pseudotyping, modifies vector tropism. Glycoproteins from a wide
variety of enveloped viruses can be used to package LVs and, as will be discussed, multiple
groups have identified envelopes that confer lung gene transfer. The envelope glycoprotein
from vesicular stomatitis virus (VSV-G) efficiently pseudotypes LVs, confers wide tropism,
and is the most commonly used envelope glycoprotein. However, in well-differentiated
airway epithelial cells, VSV-G pseudotyped LV (VSVG-LV) preferentially transduces the
basolateral surface [63, 64]. By using pretreatments or vehicles that transiently disrupt
epithelial tight junctions, VSVG-LV accesses the basolateral surface of airway cells following
luminal delivery [65]. This strategy has also been shown to greatly improve VSVG-LV in
vivo gene transfer efficiency in the lungs of mice [62].
Feline immunodeficiency virus (FIV) is a non-primate LV with a less complex genome than
HIV. Unlike HIV, wild-type FIV naturally lacks tat, vpr, vpu, and nef. In addition, FIV-based
vector has vif deleted. Additional modifications to the FIV vector, such as deleting the major
splice donor, lead to a higher transduction efficiency and transgene expression [58]. Reporter
gene studies demonstrate that FIV transduces cells in the conducting airways, bronchioles,
and alveoli [66]. FIV-mediated delivery of CFTR corrects the anion channel defect in airway
epithelia [65]. FIV pseudotyped with the baculovirus envelope glycoprotein (GP64) preferen‐
tially transduces polarized airway epithelia at the apical surface [63], results in persistent gene
expression in mice [63], and supports gene transfer to airways of pigs [66]. Additionally, FIV
vectors can be readministered to mouse airways without blocking immune responses [67]. To
prolong virus exposure to the airways immediately following delivery, formulating vector
with a viscoelastic gel increases transduction efficiency in vivo [68, 69].
Simian immunodeficiency virus (SIV)-based LV also successfully transduces airway epithelia.
SIV carries little pathogenicity for its own host; therefore, modified strains of SIV could
potentially be a safer alternative to HIV-based LVs [70]. In studies using Sendai virus envelope
proteins (F and HN) pseudotyped SIV (F/HN-SIV), a single dose persisted for the lifetime in
the nasal epithelia of a mouse and achieved a dose-dependent increase in reporter gene
expression upon vector readministration [71]. In vitro, F/HN-SIV carrying CFTR can generate
functional chloride channels [72]. Additionally, SIV transduction results in persistent trans‐
gene expression in both differentiated human airway cells and freshly excised human lung
tissue [71].
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Equine Infectious Anemia Virus (EIAV) is another non-primate lentivirus that has been
investigated as a gene transfer vector. It has been studied extensively for neurological disease
applications, such as Parkinson’s disease [73]. EIAV pseudotyped with the influenza HA
envelope can transduce neonatal mouse airways, most notably, the nasal and lung epithelium.
Readministration of HA-EIAV resulted in decreased gene transfer efficiency [74].
3.2. DNA transposons
Recombinant DNA transposons are integrating nonviral vectors that confer efficient and stable
transgene expression in a variety of cell types. The DNA transposon Sleeping Beauty (SB) was
resurrected from defective copies of a Tc1-like fish element. SB transposes its genetic cargo
into host genomic loci using its catalytic transposase activity [75]. Recombinant DNA trans‐
posons used for gene transfer applications are comprised of a two-part system; one encodes
terminal repeats (TRs) flanking a transgene of interest (transposon), and the other a catalytic
protein responsible for transposition (transposase) (Figure 1B). Since the discovery of SB, other
transposons such as piggyBac and Tol2 have also been used in gene transfer applications
(reviewed in [76, 77]). DNA transposons are attractive tools for gene therapy because they have
a large carrying capacity and integrate into the genome.
Generally, transposon-based vectors are delivered as plasmids. This poses limitations for
delivery to some somatic cell types. To improve delivery, several formulations have been
investigated. Belur and colleagues described a protocol for complexing SB with polyethyle‐
neimine (PEI) for delivery to the airways of mice [78]. The efficiency of gene transfer was
approximated to be 1%–3% 2 months post delivery. The use of liposomes has also been
investigated as an alternative transposon delivery strategy. Somatic delivery of liposome–
protamine formulated SB resulted in a higher transduction efficiency than Lipofectamine 2000
while maintaining low toxicity and biocompatibility [79]. This non-viral vector approach
overcomes biological barriers and allows for chromosomal integration; however, to date, this
strategy has not been applied to delivering CFTR to the in vivo airways.
3.3. Hybrid DNA transposon/viral vectors
Delivery of plasmid-based transposon vectors to somatic cells in vivo is inefficient. To overcome
this limitation, multiple groups have used viral vectors to deliver transposon components
(Figure 1C). Recombinant DNA transposons delivered by non-integrating viral vectors,
termed hybrid vectors, are intended to combine the advantage of efficient transduction of the
viral vector with persistent expression of the transposon, creating an integrating vector.
Adenovirus (Ad) [80, 81], adeno-associated virus (AAV) [82], and integrase-deficient lentivirus
(ID-LV) [83, 84] have all been investigated as delivery tools for DNA transposons. An inte‐
gration analysis of SB delivered by ID-HIV suggests a similar, near random, pattern as is
observed for plasmid-delivered SB [83].
Yant et al. showed that SB delivered by a helper-dependent Ad vector can integrate into the
host chromosome in a transposase-dependent mechanism [75, 80]. Interestingly, in this system,
the initial transposition of SB out of the Ad genome required the use of Flp-recombinase to
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successfully deliver the transposon transgene [80]. More recently, the generation of a hybrid
piggyBac/Ad and piggyBac/AAV facilitated delivery of a nonviral transposon. However, unlike
SB, neither piggyBac/Ad nor piggyBac/AAV required an extra recombinase step for transposi‐
tion to occur [81]. In contrast to the hybrid SB, piggyBac has not exhibited overexpression
inhibition or limitations on size of the genetic cargo [85]. PiggyBac/Ad hybrid vector success‐
fully delivered a CFTR expression cassette to primary airway epithelial cultures in vitro that
corrected the anion transport defect up to 4 months in culture. In reporter gene studies,
transgene expression persisted for the 1-year duration of the experiment in mice [81].
4. Animal models of cystic fibrosis
Animal models serve an important testing ground for somatic cell gene transfer applications.
Mice with null mutations [86-89], specific disease associated CFTR mutations [90-92], and
conditional CFTR null alleles [93] have contributed to the understanding of molecular
mechanisms of CF. However, mice do not recapitulate several aspects of CF lung disease
pathogenesis. As discussed above, many studies evaluating integrating gene transfer vector
delivery to the lungs of mice have been conducted. For these reasons, we now discuss efforts
to deliver integrating vector to new animal models CF.
4.1. CF rat
Tuggle and colleagues used zinc finger nucleases to disrupt CFTR exon 3 in rats [94]. CFTR-/-
rats recapitulate many aspects of human disease including intestinal obstruction, obstruction
of the vas deferens, and abnormalities in nasal mucus production. It is currently not clear if
CFTR null rats develop lung disease. To date, no gene correction studies have been reported
in this novel model.
4.2. CF ferret
CFTR null ferrets were developed using AAV-mediated gene targeting in somatic cells, nuclear
transfer, and cloning [95]. Unlike CF mice, CF ferrets develop early and reproducible lung
infections that make it a promising platform for testing lung-directed CF therapies [95]. There
are several potential reasons for these species differences. First, Ca++-activated Cl- channels in
the mouse airway may compensate for cAMP-mediated CFTR Cl- transport [96, 97], a pathway
that appears to be less active in humans or ferrets [95, 98-100]. Second, in humans and ferrets,
goblet cells are the predominant secretory cell type of the cartilaginous airways [101-104],
whereas in mice the analogous secretory cell type is the club cell [105, 106]. Third, SMGs are
virtually absent in murine cartilaginous airways, with only a handful in the most proximal
regions of the trachea [106, 107]. SMGs are important for airway innate immunity in the ferret
[108] and humans [109, 110], and a potentially valuable site for CFTR expression [111-114].
Lentiviral gene transfer to the wild-type neonatal ferrets using EIAV- and FIV-based vectors
expressing fluorescent reporter genes was recently reported [115]. The EIAV was pseudotyped
with hemagglutinin (HA) from avian influenza A virus [74] and the FIV vector was pseudo‐
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typed with GP64 [63]. A liquid bolus of the vector was delivered to newborn ferrets via a
tracheal incision. Significant transgene infection was noted in respiratory epithelia of all lobes
in both the conducting and small airways with both vectors. Cmielewski and colleagues
delivered VSVG-HIV expressing the LacZ reporter to the lungs of 7—8-week-old ferrets [116].
Considerably less gene transfer was observed as compared to the HA or GP64 pseudotyped
LV gene transfer in the neonatal ferrets. Currently, it is unclear if these differences are due to
the vector pseudotype, age of the ferrets, or delivery protocol; however, these data suggest
that ferrets may be useful pre-clinical models for lentiviral vector development.
4.3. CF pig
Pigs are an important model for many studies of human cardiovascular diseases, injury and
repair, surfactants, inflammation, and pulmonary diseases (reviewed in [101]). Compared to
rodents, the pig lung is anatomically and physiologically more similar to humans [117, 118]
and has been studied extensively in xenotransplantation. The prenatal maturation of the pig
lung is similar to humans and includes extensive alveolarization [119]. Pig airway branching
and cell composition is much more akin to human airways than to those of mice. The cell types
comprising the conducting airway epithelium in pigs and humans are similar, and notably
lack the high percentage of club cells typical of mice. The pig bronchial epithelium is pseu‐
dostratified and contains ciliated, basal, and goblet cells, and abundant SMGs (reviewed in
[101]). Importantly, the distribution of SMGs in the conducting airways and the CFTR-
dependent and -independent secretion of liquid and macromolecules is similar to humans
[112, 120-122].
Pigs with CFTR null and ∆F508 knock-in alleles were generated by AAV-mediated homolo‐
gous recombination and somatic cell nuclear transfer [99]. Breeding heterozygous male and
females generated homozygous CFTR-/- pigs, and their striking neonatal phenotype was
described [99, 123]. Newborn CF pigs exhibit severe disease similar to humans including
pancreatic insufficiency, meconium ileus with intestinal obstruction, absence of the vas
deferens, and evidence of liver and gall bladder disease [123]. Importantly, CFTR null and
∆F508 pigs spontaneously develop lung disease with many features similar to humans with
CF including bacterial infection, inflammation, abnormal mucociliary clearance, bronchiecta‐
sis, and remodeling.
In a recent study, we compared HIV- and FIV-based lentiviral vectors in well-differentiat‐
ed human and pig airway epithelia [66]. FIV transduced pig airway epithelia with greater
efficacy than HIV, but both FIV and HIV transduced human airway epithelia with equal
efficacy [66]. We further screened a number of envelope glycoproteins and identified GP64
as one of the most efficient pseudotypes for transduction and persistent expression in both
pig and human epithelial cells [66]. A mCherry marker virus was delivered to wild-type
pigs 4 weeks of age. A bolus dose of GP64-FIV vector was delivered to the ethmoid sinuses
or to the tracheal lobe through a catheter threaded through the suction channel of a pediatric
bronchoscope. We estimated the range of transduction efficiencies in the pig airways to be
from <1 to 7%. In future studies,  we will  deliver CFTR expressing vector to CF pigs to
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determine the preferred gene transfer targets and the level of CFTR correction required to
prevent or slow disease progression
5. Outcome measures
In pre-clinical studies of CF gene therapy, it is vital to define metrics of correction before the
studies are initiated. It would be naïve to simply deliver vector to the airways and “look and
see” if the airway disease is cured. CF is a complex disease with many phenotypic features and
clearly defining the disease progression in an untreated CF animal model is vital. As experience
is gained with new animal models, additional assays for correction will be established and
refined. Importantly, these metrics may apply to multiple gene correction but may not be
feasible in all animal models.
5.1. Quantitative real-time PCR and CFTR protein expression
Quantitative real-time RT-PCR is a sensitive assay for measuring vector expressed CFTR
mRNA [123]. At progressive time-points post vector delivery, whole tissue or brushings of
nasal or tracheobronchial epithelia can be obtained. Silent mutations can be engineered into
the vector expressed CFTR cDNA so that transgene expression can be differentiated from
endogenous CFTR. Using a similar strategy, vector genome copy number can be estimated.
Genomic DNA from a portion of the same tissue or epithelial brushings can be purified and
copy number estimated by normalizing to endogenous DNA and a standard curve. Appro‐
priate controls would include wild type and untreated affected littermates. To identify cells
expressing the CFTR protein, immunohistochemistry and immunofluorescence protocols have
been reported [123]. Using these approaches, the percentage of cells expressing CFTR and the
cell types expressing CFTR can be determined [124].
5.2. Functional correction
Nasal potential difference (NPD) is an established assay for demonstrating in vivo correction
of CFTR-dependent Cl- transport [125-127]. For many of these studies, vector was delivered
nasally and the NPD was used as evidence of CFTR complementation. Ideally, for integrating
vectors, predelivery, early post-delivery, and late post-delivery timepoints in the intrapulmo‐
nary airways should be measured. As early as 1 week after gene transfer, the nasal voltage and
its response to amiloride, low Cl-, and cAMP agonists can be measured [90, 123, 128]. Animals
could be followed with serial monthly nasal voltage measurements over a 12-month or longer
period to document persistence of expression. Importantly, CFTR is an anion channel that
conducts both Cl- and HCO3-. As mentioned above, correcting ~10% of cells is often cited as a
benchmark for restoring Cl- transport and correcting the clinical phenotype. However, other
studies also suggest that defective HCO3- transport might be relevant to disease. Multiple
studies of CF mouse cervical mucus [46, 47], CF mouse small intestinal mucus [48], and human
CF nasal SMGs [49] support the importance of CFTR-dependent HCO3- transport in CF
pathogenesis. Loss of CFTR-dependent HCO3- transport acidifies liquid produced by surface
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epithelia [129, 130] and secretions from SMGs [49]. Thus, measurements of HCO3- transport
may also be an important metric of functional correction.
As a result of abnormal CFTR-dependent HCO3- secretion, airway surface liquid pH is
acidified. The ASL of primary cultures of CF pig airway epithelia [130], newborn CF pig
airways [130], and the nasal pH of newborn babies with CF [131] is acidic. In CF pigs, the
acidity has been shown to impair bacterial killing [130]. In addition, there are new techniques
to measure mucus viscosity, mucociliary clearance (MCT), and lung function in large animal
models [101]. Importantly, defects in airway MCT and SMG mucus detachment recently were
identified in CF [132]. The bacterial killing defect is a quantifiable characteristic of CF airways.
Bacterial killing is impaired as a result of reduced bicarbonate anion secretion and increasing
ASL pH rescues bacterial killing [130].
5.3. Reduced infection and inflammation
A goal of gene therapy for CF is to prevent the onset or reduce the progression of lung disease.
Signs of reduced infection and inflammation in treated animals can be visually inspected in
the airways. Bronchoscopy can be used to detect signs of inflammation, such as mucosal
inflammation and excessive purulent secretions. Total cell counts, cell differentials, and
cytokine levels are obtained from bronchoalveolar lavage (BAL) as standard assay for infection
and inflammation. In addition, standard quantitative microbiologic techniques are used to
identify and quantify BAL bacteria [133]. Biopsies can also be obtained from larger animal
models such as the CF pig. These samples can also be used for sequencing-based analyses. As
we learn more about the disease progression in new animal models of CF, improved metrics
of functional correction are being developed. High-resolution computerized tomography
(HRCT) facilitates detailed structural analysis of the airways [101]. HRCT scans can discern
anatomic changes in the airways over time in control and treated animals [134].
6. Challenges to pulmonary gene transfer with integrating vectors
6.1. Delivery
The lung is an attractive target for gene therapy because, unlike most other tissues, the vector
can be topically delivered. Vector delivery to the airways of mice, rats, and newborn ferrets is
most easily accomplished by nasal or intratracheal bolus delivery of vector resuspended in a
liquid vehicle such as buffered saline [135], LPC [60, 62], or a viscoelastic gel [68, 69]. In small
animals, bolus delivery using a relatively small volume of vector (25-50 μl) can achieve
widespread gene expression throughout the airways. However, in large animal models such
as pigs or sheep (and ultimately humans), aerosolization will likely be required to achieve a
widespread pulmonary distribution. In general, devices for generating airborne vector fall into
three categories: aerosolizing catheters, nebulizers, and atomizers. All of these devices convert
liquids into particles small enough to be respired.
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Aerosolizing catheters convert liquids into particles at the point of expulsion. Typically, an
aerosolizing catheter is first passed into the trachea and then the vector is instilled. The
Microsprayer® (PennCentury) and the AeroProbe® catheter (Trudell Medical International)
are examples of delivery systems for this application. According to the manufacturer, it is
possible to generate particles with aerodynamic diameters of 4–8 μm. The Trudell AeroProbe
was previously used to aerosolize helper-dependent adenovirus vectors to rabbit airways [136,
137] and to deliver Sendai virus vectors to sheep [138]. Since Sendai virus and lentiviruses are
both enveloped, it is likely that this approach is feasible with lentiviral vectors. In addition,
aerosolized VSVG-LVs have been successfully delivered to the airways of mice [139].
Successful vector aerosolization has been reported in mice [140], rabbits,[136, 137], pig [141]
and sheep airways [142, 143]. By 2–3 weeks of age, wild type pigs are large enough to be sedated
and have a pediatric bronchoscope passed into the trachea. The AeroProbe® catheter can be
passed to the carina via the bronchoscope suction channel with the animal breathing sponta‐
neously. In this way, an integrating vector can be aerosolized and targeted to specific bronchial
segments.
In the case of nebulizers, the liquid is first converted into mist and then passively inhaled.
Using this strategy, a plasmid-based vector was delivered to the airways of CF patients in a
phase IIB gene therapy trial [144]. This approach could potentially be used to deliver DNA
transposon or hybrid vectors. However, this strategy may not be feasible with enveloped viral
vectors because this class of vectors may not be stable enough to withstand nebulization. In
addition, nebulization requires a large volume of concentrated material; therefore, would be
the least economic delivery strategy for LVs.
Atomizers are a subclass of aerosolizing catheters that deliver larger sized particles. An
atomizer, such as the MADgicTM (LMA) atomizer, delivers large droplets (~30–90 μm in
diameter), which may vary in size depending on the force applied to the syringe plunger. This
type of device is often used to topically deliver medications to the airways [145]. Our group
has observed that this type of atomizer is an effective delivery device for multiple viral vectors
including FIV, particularly when formulated with a viscoelastic material such as methylcel‐
lulose.
6.2. Insertional mutagenesis
Since persistent gene expression from lentiviral vectors requires genomic integration, they
show promise for treating life-long genetic diseases; however, there is inherent risk when
introducing a transgene with integrating vectors. Insertional mutagenesis may disrupt normal
cell functions by inactivating an essential host gene or inappropriately causing expression of
an undesirable gene. The risk will vary depending on the vector used, the transgene cassette,
and the cell type targeted. In many cases, enhancer effects pose the greatest danger. So far,
malignant cell transformation after vector-mediated insertional mutagenesis has only been
observed in three clinical entities (X-linked severe combined immunodeficiency (SCID-X1),
chronic granulomatous disease (CGD), and Wiskott–Aldrich syndrome (WAS)), all of which
occurred in conjunction with the use of first-generation gamma-retroviral vectors harboring
LTRs with strong enhancer/promoter sequences [146-150]. These studies were conducted in
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immunocompromised patients where gene transfer conferred a selective advantage to
corrected cells. The vector and disease settings likely influenced the risks for insertional
mutagenesis and subsequent clonal expansion. Modern LVs are engineered to lack enhancer/
promoter sequences within the LTRs and delivering CFTR to somatic cells has no known
selective advantage. Considerable effort has been put toward mapping integration patterns
and determining the functional consequences of LVs and retroviral vectors (reviewed in [151,
152]). LV integration analyses conducted on adrenoleukodystrophy clinical trial patients
demonstrate that the genomic distribution maintain a polyclonal pattern [153]. Montini and
colleagues demonstrated that LV integrations, even at high vector titer loads, did not accelerate
tumorigenesis in tumor prone mice. In contrast, gamma-retroviral vector transduction
triggered a dose-dependent acceleration of tumor onset [154].
The burden of proof has fallen on LV researchers to demonstrate that LVs do not cause
cancer via insertional mutagenesis. It is unlikely that this can ever be demonstrated with
absolute certainty; however, the evidence to date suggests that current LVs are considera‐
bly safer than the gamma-retroviral vectors that were first brought to clinical trials. In fact,
results  from human clinical  trials  using LVs are encouraging and the feasibility of  gene
therapy  for  monogenetic  diseases  is  now  firmly  established  [155].  Recent  promising
examples  include  Wiskott–Aldrich  Syndrome  [156,  157],  metachromatic  leukodystrophy
[158,  159],  acute  lymphoid  leukemia  [160],  lymphoma [161,  162],  and  multiple  primary
immuno-deficiencies [163].
7. Conclusions
Within  a  year  of  the  discovery  of  CFTR,  investigators  validated  the  concept  that  gene
replacement could reverse the ion transport defect in vitro,  suggesting that gene therapy
may  be  possible  [164,  165].  We  and  others  have  demonstrated  that  CFTR  delivery  by
integrating vectors can correct the CF anion defect in vitro and in vivo, and although further
pre-clinical trials are warranted, there is great potential for translating this strategy to the
clinic. As discussed, estimates of the percent of CF epithelia requiring correction vary and
there  is  debate  about  which  cell  types  must  be  corrected to  achieve  phenotypic  correc‐
tion; however, interest in CF gene therapy remains strong as barriers to gene transfer are
identified,  outcome  measures  are  established,  CF  animal  models  with  lung  disease  are
developed, and better delivery systems are engineered. Demonstration of corrective gene
transfer to pristine newborn lungs in CF animal models is a vital first step before looking
ahead to correcting more diseased lungs. Newborn screening for CF is now established in
all 50 states, allowing early disease detection. This offers an opportunity to introduce an
integrating therapeutic gene transfer vector to the airway epithelium prior to the onset of
chronic infection and inflammation. This strategy is a potentially life-long curative therapy
regardless of the disease-causing mutation.
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